Sebastien Bergeron's Biography

Sebastien Bergeron, Founder and CEO, Parallex BioAssays Inc.

Sebastien Bergeron is the founder and CEO of Parallex BioAssays. He completed a Ph.D. in physiology and endocrinology, with a focus on type II diabetes. As a postdoctoral fellow in the Biomedical Engineering department at McGill University, he developed a strong interest in microfluidics and immunoassay miniaturization. He drove the development of a new microarray format, called the SnapChip™. This cross-reaction-free platform offers high quality results while permitting rapid, flexible and customized multiplexed immunoassay development. In 2015, Sebastien founded Parallex BioAssays to make this technology available to the scientific community.

The SnapChip™ for a Precise Chip-to-Chip Transfer of Nanodroplets

Wednesday, 19 June 2019 at 16:45

Add to Calendar ▼2019-06-19 16:45:002019-06-19 17:45:00Europe/LondonThe SnapChip™ for a Precise Chip-to-Chip Transfer of NanodropletsPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Multiplexed sandwich immunoassays are a powerful technique to measure multiple protein concentrations simultaneously. However, multiplexed assays are prone to cross reactivity effects and can generate false positive signals due to a lack of antibody specificity and selectivity. This is a known weakness of multiplexed assays that is mitigated by months of assay optimization and validation.

Parallex BioAssays replaced the “detection soup” of antibodies by an array of nanodroplets and offers a new CHIP-to-CHIP approach to deliver the detection antibodies precisely to their cognate spots of capture antibodies. As a result, a cross-reaction free chip consisting of an assembly of parallelized assays, physically isolated from each other. The advantages include the possibility to mix-and-match assays and create unique combinations, such as isoforms and phospho-specific antibodies side-by-side. This makes our approach to cell signaling studies (e.g. Akt activation pathway) a rapid and easy alternative to performing dozens of western blots.

The SnapChip™ represents a new format of liquid handling platforms. Beyond exclusive immunoassays, it creates the opportunity to miniaturize and multiplex enzyme activity and cell-based assays in nano-compartments. Current and future applications will be discussed.

Add to Calendar ▼2019-06-18 00:00:002019-06-19 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2019Point-of-Care, Biosensors and Mobile Diagnostics Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors